Morrison Foerster covers the pharmaceuticals, biologics, diagnostics, personalised medicine, medical devices, medicinal chemicals, and vaccines sectors. The firm is also lauded for its specialisms in IP protection, licensing, pharmacovigilance, and clinical and commercial supply agreements. Other key areas are US-China investigations, drug and device safety, cybersecurity, corruption, compliance, and cross-border transactions. The practice is co-led by managing partner of the Beijing and Shanghai offices, Chuan Sun, who acts for major life sciences clients, including healthcare private equity firms; and Hong Kong-based Gordon Milner, an expert in pharmaceutical and biotechnology industry-related technology projects. Beijing-based Sarah Wang advises on corporate commercial and technology transactions in the life sciences sector; while B Chen Zhu and Tyler Xiu are other names in Hong Kong to note.
Testimonials
Collated independently by Legal 500 research team.
‘MOFO provides very comprehensive legal services to clients.’
‘Chuan Sun is a very experienced healthcare industry lawyer - outstanding.’
Key clients
- Ally Bridge Group
- Celadon Partners
- EdiGene
- Jamieson Laboratories
- Triastek
Work highlights
- Advised Jamieson Laboratories and its parent company Jamieson Wellness on their partnership with international private equity firm DCP Capital.
- Advising Celadon Partners on its launch of GeneFab, a contract research, development, and manufacturing organisation (business partnering with the cell and gene therapy industry).
- Advised Ally Bridge Group on various growth, late stage and public life sciences investments across the US and Europe, including the $28.5m financing round of Vida Health, and the $80m Series D equity investment financing in LightForce Orthodontics.
Lawyers
Practice head
The lawyer(s) leading their teams.
Chuan Sun, Gordon Milner